Plus therapeutics inc
PSTV 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
PSTV 近期報酬表現
-4.17%
Plus therapeutics inc
-0.98%
同產業平均
-0.22%
S&P500
與 PSTV 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
TSBX | Turnstone biologics corp | - | 2 分 | 4 分 | 1 分 | 1 分 | |
BCDA | Biocardia inc | 3 分 | 2 分 | 2 分 | 1 分 | 1 分 | |
TENX | Tenax therapeutics inc | 4 分 | 2 分 | 2 分 | 1 分 | 1 分 | |
CYTO | Altamira therapeutics ltd | - | 2 分 | 2 分 | - | 1 分 | |
CLLS | Cellectis sa - adr | 3 分 | 3 分 | 2 分 | 1 分 | 1 分 |
- TSBX Turnstone biologics corp價值 -趨勢 2 分波段 4 分籌碼 1 分股利 1 分查看更多
PSTV 公司資訊
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company's Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.